Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Gemtuzumab ozogamicin (GO) improves outcomes when added to intensive AML chemotherapy. A meta-analysis suggested the greatest benefit when combining fractionated doses of GO (GO3) with 7 + 3. To test whether GO3 can be safely used with high intensity chemotherapy, we conducted a phase 1/2 study of c...

Full description

Bibliographic Details
Main Authors: Colin D. Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, Anna B. Halpern, Jacob S. Appelbaum, Mary-Elizabeth M. Percival, Paul C. Hendrie, Vivian G. Oehler, Siobán B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Elihu H. Estey, Roland B. Walter
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
acute myeloid leukemia (AML)
adults
antibody-drug conjugate
chemotherapy
CD33
CLAG-M
Online Access:https://www.mdpi.com/2072-6694/14/12/2934

Internet

https://www.mdpi.com/2072-6694/14/12/2934

Similar Items